Articles Related to anticancer

Targeting mutant proteins and associated signaling pathways of driver oncogenes by small molecule kinase inhibitors (KIs) are a promising strategy of cancer therapy. However, despite the initial success of treatment, KIs often become ineffective as intrinsic and acquired resistance. This article reviews the English-language literature to explore the underlying mechanisms of drug resistance and to present a challenge for developing drugs to overcome resistance. Mechanisms of acquired resistance include 1) the selection of pre-existing subclones with other mutations, 2) the emergence of secondary mutations in the target kinase domain, 3) upregulation of kinases both within the same kinase family and their related kinase families, as well as activation of alternative bypass pathways, 4) epithelial-mesenchymal transition, 5) overexpression of pro-survival Bcl-2 family proteins and 6) drug efflux mechanisms. Currently available methods are to obtain tumor biopsy samples at recurrence or progression if the tumor lesion is accessible to a biopsy and to use the second- and third-generation KIs based on the individual need of each patient. Furthermore, recent computational challenges provide design principles to prevent the development of drug resistance. In conclusion, we provide an overview of the postulated resistance mechanisms and highlight the future direction of computational structure-based design of new potent KIs.

View complete article: PDF  |  Full-text

Objective: To evaluate the compliance of chemotherapy administration duration by comparing the peripheral venous catheter (PVC) route with the implantable venous access device (IVAD).Keywords: Chemotherapy; Gravity perfusion; Peripheral venous; Implantable venous access deviceIntroduction Methods: This was a retrospective study that analyzed 566 cycles of chemotherapy administered by PVC at the Cancer Unit of Yalgado Ouédraogo University Hospital and 258 cycles administered by IVAD at the Oncology Department of Treichville University Hospital in Abidjan. We compared the differences between the programmed duration of chemotherapy and the actual duration of administration according to the two routes of administration.

View complete article: PDF  |  Full-text

Eugenol (EU) and ibuprofene (IBU) were covalently bound to a bi-functionalized PEG, used as molecular carrier of drugs and the release kinetics of the two bioactive molecules was studied in vitro in buffer solution at pH 7.4, in simulated gastric fluid and in mouse plasma.

View complete article: PDF  |  Full-text

The first patient was a 77 year old man who had been on abiraterone for 12 months before his phosphorous was checked. At that point, it was 0.6 mg/dl, which is severely decreased. A full work up for hypophosphatemia showed normal parathyroid hormone and 25-hydroxyvitamin D. A urine study showed inappropriate excretion of phosphorous along with aminoaciduria and normoglycemic glucosuria.

View complete article: PDF  |  Full-text

Researchers have been inventing new drugs since time immemorial. Of late it is established that the development of new drugs alone is not sufficient to ensure progress in drug therapy. The missing link is a potential strategy.It involves the apt selection of drug carrier systems.

View complete article: PDF  |  Full-text  | Digital

Cancer is a highly heterogeneous disease characterised by continuous uncontrolled growth and expansion of abnormal cells. In general, in tumor cells the signalling pathways regulating cellular processes, as cell growth and division and cell to cellcommunication result strongly altered.

View complete article: PDF  |  Full-text  | Digital